Bruker (NASDAQ:BRKR) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Bruker (NASDAQ:BRKR) in a research report report published on Tuesday morning, Benzinga reports. The brokerage issued an overweight rating and a $78.00 price objective on the medical research company’s stock.

Other research analysts have also issued reports about the company. StockNews.com lowered Bruker from a buy rating to a hold rating in a research report on Tuesday, May 21st. Bank of America cut their price objective on Bruker from $95.00 to $90.00 and set a buy rating on the stock in a research report on Monday, May 20th. Stifel Nicolaus cut their price objective on Bruker from $81.00 to $77.00 and set a hold rating on the stock in a research report on Monday, May 20th. Jefferies Financial Group began coverage on Bruker in a research report on Monday, June 3rd. They issued a buy rating and a $85.00 price objective on the stock. Finally, TD Cowen cut their price objective on Bruker from $74.00 to $72.00 and set a hold rating on the stock in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $81.40.

Bruker Trading Up 0.1 %

Shares of BRKR opened at $63.95 on Tuesday. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $9.29 billion, a P/E ratio of 23.25, a price-to-earnings-growth ratio of 2.39 and a beta of 1.20. The stock’s fifty day simple moving average is $63.87 and its 200 day simple moving average is $74.90. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. The business had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the company posted $0.50 EPS. On average, equities research analysts forecast that Bruker will post 2.66 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Monday, September 2nd will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.31%. Bruker’s dividend payout ratio is presently 7.27%.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its stake in Bruker by 3.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 8,080,071 shares of the medical research company’s stock worth $593,724,000 after purchasing an additional 239,336 shares in the last quarter. TD Asset Management Inc grew its stake in Bruker by 7.4% in the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock worth $168,036,000 after purchasing an additional 123,984 shares in the last quarter. Brown Advisory Inc. grew its stake in Bruker by 2.3% in the fourth quarter. Brown Advisory Inc. now owns 1,590,151 shares of the medical research company’s stock worth $116,844,000 after purchasing an additional 35,873 shares in the last quarter. Congress Asset Management Co. MA grew its stake in Bruker by 3.5% in the first quarter. Congress Asset Management Co. MA now owns 1,414,362 shares of the medical research company’s stock worth $132,865,000 after purchasing an additional 47,301 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.